Overview

A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Tofacitinib